NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ALL
FIGURES IN CANADIAN DOLLARS UNLESS OTHERWISE SPECIFIED.
LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- BLVD Centers (CSE:BLVD) today announced it has allocated $25,000 to support
medical cannabis research studies conducted at major U.S. universities or under the direction of qualified, independent university
faculty. BLVD will maintain a particular focus on supporting research on the use of cannabis to control addiction and cravings.
BLVD’s first allocation has been made to the University of California – Los Angeles (UCLA) Cannabis Research Initiative
(https://www.uclahealth.org/cannabis/). The choice to provide funding for this project is in part due to the large 18-bed facility
in Los Angeles, California that BLVD Centers owns.
“We are really at the beginning of understanding the impact cannabis can have on our patients,” said Jacob Gamble, CEO of BLVD
Centers. “Our inpatient detox centers serve patients suffering from cravings to opioids daily. By providing funding to several
cannabis studies, we aim to build relationships to stay at the forefront of research in this arena as well as being a part of the
effort to find new ways to treat our patients. We do not intend to start our own research. Instead, we will support specific
projects that have a nexus to our expected patient base, which are led by highly respected independent academic leaders.”
For more information contact:
BLVD Centers Corporation
Jacob Gamble
CEO and Executive Director
(424) 372-1123
investorinfo@BLVDcenters.com
www.BLVDir.com
